Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Avapritinib vs Regorafenib in Advanced GIST
NCT03465722Phase 3Completed
- Sponsor
- Blueprint Medicines
- Start
- Mar 2018
- Primary completion
- Mar 2020
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 18
01
Overview
A Phase 3 trial of avapritinib in gastrointestinal stromal tumor (GIST), sponsored by Blueprint Medicines. Started Mar 2018; status: completed.
02
Drugs
avapritinib
03
Conditions
gastrointestinal stromal tumor (GIST)
Beyond the preview
Go deeper on NCT03465722.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03465722.